In plain English
PT-141 is a peptide that increases sexual desire and arousal by acting on the brain’s melanocortin system. Unlike Viagra-type drugs, which work on blood flow, PT-141 works on desire itself. It is FDA-approved as Vyleesi for low sexual desire in premenopausal women and is also widely used by men.
What it's used for
- Low sexual desire in premenopausal women (Vyleesi)
- Low libido in men and women
- Erectile difficulties linked to low desire
- Arousal support
Benefits
In human studies, PT-141 has shown:
- Increased sexual desire and less distress about low desire in women (the RECONNECT studies behind Vyleesi)
- Improved erections in men in earlier studies, including some who did not respond to Viagra-type drugs
- Effects that start within about an hour and can last several hours
Users report stronger desire and arousal for both men and women.
How it works
In simple terms: PT-141 switches on desire pathways in the brain.
It activates melanocortin receptors, mainly MC4R, in the hypothalamus. These pathways influence sexual motivation and arousal, and also release dopamine in brain areas linked to desire. Because it works centrally rather than on blood vessels, it can help people whose issue is desire rather than circulation.
Development history
- 1990s: Discovered when researchers testing Melanotan II for tanning noticed strong effects on arousal.
- 2000s: Developed by Palatin Technologies as bremelanotide; an early nasal version was dropped and development moved to injection.
- 2019: FDA-approved as Vyleesi for low sexual desire in premenopausal women.
Typical protocols
Vyleesi is used as below. Users of research vials report similar doses.
| Use | Dose | Timing | Limits |
|---|---|---|---|
| Vyleesi (prescribing label) | 1.75 mg | At least 45 minutes before sexual activity | No more than 1 dose in 24 hours and 8 doses a month |
| Research vials (users report) | 0.5–2 mg | 1–2 hours before activity; many start at 0.5–1 mg | Same limits commonly followed |
Cycling
Used as needed rather than daily. Users generally keep to no more than one dose a day and a few doses a week.
Administration options
Subcutaneous injection in the belly or thigh, used as needed.
Reconstitution and dosing calculator
Research PT-141 usually comes in 10 mg vials and is commonly mixed with 2 mL of bacteriostatic water.
Draw your syringe to
– units
- Volume to draw
- –
- Concentration
- –
- Each unit holds
- –
- Doses per vial
- –
Show the math
This tool does arithmetic only. It does not choose a dose or confirm that any substance is right for you. Double-check every result against your syringe and your clinician’s instructions.
Side effects and safety
- Most common: nausea (common, especially with the first dose), flushing, headache and injection-site reactions. Starting with a lower dose reduces nausea.
- A temporary rise in blood pressure and fall in heart rate after a dose; people with uncontrolled high blood pressure or heart disease should not use it.
- Darkening of patches of skin (gums, face, breasts) has been reported with repeated use.
- Not for use during pregnancy.
Common stacks
Users report combining it with Viagra-type drugs or with kisspeptin, but these combinations have not been studied. Combining PT-141 with blood pressure-raising substances is not advised.
Storage
Vyleesi autoinjectors: store at room temperature, per the label.
Research powder: refrigerate; after mixing, refrigerate at 2–8 °C and use within about 4 weeks.
Compare with
- Melanotan II: the parent peptide; also causes tanning and has more side effects.
- Viagra-type drugs (PDE5 inhibitors): work on blood flow rather than desire.
- Kisspeptin: acts on reproductive hormones rather than melanocortin receptors.
Frequently asked questions
How long before activity should I take it?
The label says at least 45 minutes; users often allow 1–2 hours.
Does it work for men?
It is approved for women, but studies and user reports show it also increases desire and erections in men.
How do I reduce the nausea?
Start with a lower dose, and avoid a heavy meal beforehand. Nausea usually lessens with later doses.
Will it tan me like Melanotan II?
It is much weaker at the tanning receptor, though some skin darkening has been reported with repeated use.
References
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908.
- Vyleesi (bremelanotide injection), US prescribing information.